Cancer Immunotherapy I

  • The field of anticancer therapeutics (excluding surgery and radiation) is divided into three primary pharmacological paradigms:

    • Cytotoxic Chemotherapy: This is the oldest and most common mainstay of clinical cancer therapy. These drugs non-specifically target all rapidly proliferating cells. This lack of specificity causes them to attack both malignant cancer cells and healthy normal cells.

    • Understanding Cytotoxic Chemotherapy: It is essential to know that chemotherapy drugs are often classified based on their mechanisms of action, such as alkylating agents that add alkyl groups to DNA or antimetabolites that mimic the building blocks of DNA, disrupting cancer cell division.

    • Targeted Therapies: These represent newer agents designed to interact with specific molecular alterations unique to cancer cells. These are often informed by individual genetic alterations or the upregulation of specific signaling pathways. Consequently, they tend to be more specific to cancers and exhibit less systemic toxicity than traditional chemotherapy.

    • Examples of Targeted Therapies: Drugs like Trastuzumab target the HER2 protein in breast cancer, highlighting how treatments can be customized according to a person’s specific cancer.

    • Immunotherapy: This rapidly growing field leverages the host's own biological defenses to identify and eliminate cancer cells.

    • Importance of Immunotherapy: It works by harnessing the immune system, which is our body’s natural defense against infections and diseases. Understanding this approach may involve knowing about various types of immune cells, such as T cells and how immune checkpoints can be manipulated to enhance the immune response against tumors.

Definition and Goals of Cancer Immunotherapy

  • Broad Definition: Immunotherapy is the treatment of any disease (not exclusive to cancer) by inducing, enhancing, or, in certain medical contexts, suppressing an immune response.

  • Application in Oncology: In cancer treatment, immunotherapy aims to stimulate the immune system to track down and attack tumor cells using mechanisms similar to those employed against viruses and bacteria.

  • Exogenous Supplementation: Cancer immunotherapy can also involve supplementing the host immune system with man-made, exogenously provided components to enhance its natural potency, such as monoclonal antibodies.

  • Learning Objectives: The scope of this study includes:

    • Understanding the bird's eye view of the antitumor immune response principles, including how immune cells recognize and respond to tumors.

    • Learning the basic mechanisms of action for every class of cancer immunotherapy, such as CAR T-cell therapy, which is a notable advancement in this field.

    • Identifying challenges, limitations, and specific toxicities (adverse effects) associated with these treatments, as immunotherapies can also inadvertently lead to immune-related adverse events if not properly managed.

Historical Background: The Father of Cancer Immunotherapy

  • Although currently viewed as a modern "booming" approach, cancer immunotherapy dates back to the end of the 19th19^{th} century.

  • William Coley: Known as the "Father of Cancer Immunotherapy."

  • Coley's Toxin: He developed a mixture consisting of heat-inactivated bacteria, which were injected intratumorally.

  • Outcomes and Skepticism: Coley observed significant tumor regressions, and the treatment was briefly advertised as a groundbreaking therapy. However, because Coley did not maintain rigorous laboratory notebooks or reproducible protocols, he faced significant skepticism. Understanding this history can provide important lessons about the need for scientific rigor in developing new treatments.

  • Transition to Radiotherapy: Following the decline of Coley's Toxin, he was encouraged to explore radiotherapy at Memorial Sloan Kettering (now Memorial Sloan Kettering Cancer Center in New York City), where he successfully advanced that field into clinical practice. The shift in focus highlights how scientific discovery often requires adaptation and change based on results.

The Cancer Immunity Cycle

  • The process of cancer immunity functions as a continuous cycle starting at the tumor site:

    • Phase 1: Antigen Release: Tumor cells die via apoptosis (programmed cell death) or necrosis (cell death due to injury), leading to the release of a significant load of cancer antigens. Even living cancer cells present antigens on their surface, which serve as signals to the immune system.

    • Phase 2: Antigen Processing: These tumor antigens are captured by host dendritic cells (DCsDCs) for processing and activation. Dendritic cells act as messengers between the innate and adaptive immune systems.

    • Phase 3: Priming and Activation: Dendritic cells migrate to the lymph node and present these antigens to TT cells, priming and activating the TT cell response, which is crucial for targeting cancer cells.

    • Phase 4: Infiltration: Activated TT cells patrol the body, find the tumor site, and extravasate into the tissue, where they can begin to attack and destroy tumor cells.

    • Phase 5: Recognition and Lysis: TT cells recognize specific tumor antigens on the surface of malignant cells and mediate cell killing, which is essential for eliminating the tumor.

    • Cycle Restart: The destruction of tumor cells releases even more antigens, restarting and amplifying the cycle, enhancing the immune system's ability to combat cancer.

Mechanisms of Antigen Presentation and Types of Tumor Antigens

  • Cross-Presentation: Antigens presented on MHCMHC class II on tumor cells are captured and processed by host Antigen-Presenting Cells (APCsAPCs). These APCsAPCs then present the antigens to CD8+CD8+ cytotoxic TT cells to initiate priming. Understanding how the immune system identifies and presents tumor antigens is crucial for developing effective immunotherapies.

  • Types of Tumor Antigens:

    • Normal Self-Antigens: Displayed by normal cells; these do not trigger a TT cell response.

    • Mutated Self-Proteins: Resulting from the high rate of mutagenesis and genetic instability in tumors. These "broken" or variant proteins are unique to the tumor and can drive an immune response

    • Oncogene/Tumor Suppressor Products: Proteins directly participating in cancer genesis (e.g., mutated tumor suppressor

    • Overexpressed or Aberrantly Expressed Proteins: Normal proteins expressed at the wrong time or in the wrong place. For example, breast cancers in postmenopausal women may express milk proteins not normally found at that age

    • Viral Antigens: Antigens derived from oncogenic viruses or the abnormal reactivation of endogenous or exogenous viruses that can lead to the development of cancers, which is why certain viruses are considered risk factors for cancer.

Bone Marrow Transplant (BMT) as Immunotherapy

  • Bone marrow transplant is one of the earliest forms of cancer immunotherapy, primarily used for leukemias and hematologic malignancies.

  • The Procedure: After wiping out the patient's diseased marrow with intensive chemotherapy, they are "rescued" with donor bone marrow. This way, the patient receives healthy stem cells to rebuild their blood and immune systems.

  • Graft-versus-Tumor (GVT) Effect: The donor-derived immune system provides a response that tracks and kills residual tumor cells. This effect is a primary mechanism for the success of BMTBMT and illustrates how using donor cells can help overcome cancer.

  • Graft-versus-Host Disease (GVHD): A significant challenge where the donor immune system recognizes the patient's normal tissues as foreign and attacks them. Extensive GVHDGVHD is difficult to manage clinically and can be fatal. Understanding GVHD is crucial for improving patient outcomes following transplants.

Monoclonal Antibodies (mAbs) Nomenclature

  • Systematic naming allows clinicians to identify the structural origin of the antibody:

    • Murine Antibodies: Produced in mice. Consist entirely of murine structures. High risk of "cytokine storm" and low stability due to being recognized as foreign by humans, which can lead to severe side effects.

    • Chimeric Antibodies (Suffix: -ximab / Code: ZZ): Approximately 75\text{%} human, with murine variable regions.

    • Humanized Antibodies (Suffix: -zumab / Code: ZOOZOO): Approximately 95\text{%} human, only 5\text{%} originating from mouse sources, reducing the risk of adverse reactions.

    • Mixed Chimeric/Humanized (Suffix: -xizumab / Code: ZZOOZZOO): A hybrid of the two structures, reflecting advancements in antibody development.

    • Fully Human Antibodies (Suffix: -umab / Code: UU): Derived entirely from human sequences, providing the best compatibility and efficacy in treatment.

Examples and Mechanisms of Monoclonal Antibody Therapies

  • Rituximab: An anti-CD20CD20 chimeric monoclonal antibody.

    • Target: CD20CD20, a BB cell surface marker found on normal and malignant BB cells.

    • Use: Refractory BB cell malignancies (e.g., Non-Hodgkin's lymphoma, large cell BB cell lymphoma) and some autoimmune diseases, demonstrating the versatility of monoclonal antibodies.

    • Side Effects: First-dose infusion-related symptoms (allergic reactions to the murine component). On-target toxicities include BB cell depletion, immunodeficiency, viral reactivation, bowel perforations, and delayed-onset neutropenia (via FcγFc\text{γ} receptors). Understanding these side effects helps in managing patient care effectively.

  • Mechanism of Action for Ritualistic Immunotherapy:

    • Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC): Effector cells recognize the bound antibody via FcγFc\text{γ} receptors and kill the target cell, highlighting how the immune system can be manipulated to fight cancer.

    • Complement-Dependent Cytotoxicity (CDC): Bound antibodies recruit complement to form a Membrane Attack Complex (MACMAC), leading to cell lysis, offering potential benefits in reduction of tumoral mass.

  • Trastuzumab (Herceptin): An anti-HER2HER2 (or ERBB2ERBB2) humanized antibody. Primarily considered a "targeted therapy" because its main action is inhibiting the oncogenic signaling pathway of ERBB2ERBB2, rather than just immune recruitment, showing the progress in personalized cancer treatments.

Antibody-Drug Conjugates (ADCs) and Bispecific T Cell Engagers (BiTEs)

  • Antibody-Drug Conjugates (ADCs): Utilize the antibody for targeting while a payload performs the killing.

    • Ibrutinib-2009: Anti-CD20CD20 antibody conjugated to a radioactive isotope to concentrate radioactivity in the tumor while minimizing systemic exposure, showcasing innovative therapeutic strategies.

    • Gemtuzumab Ozogamicin (Mylotarg): Anti-CD33CD33 humanized antibody conjugated to an anti-tumor antibiotic that causes DNA damage. Used for Acute Myeloid Leukemia (AMLAML). FDA History: Approved in 20002000, withdrawn in 20022002 due to side effects/resistance, and re-approved in 20172017 with refined dosing, emphasizing the importance of ongoing research and development in cancer therapies.

  • Bispecific T Cell Engagers (BiTEs): Use linked variable regions from two different antibodies.

    • Blinatumomab: Links anti-CD19CD19 (tumor target) to anti-CD3CD3 (TT cell receptor).

    • Effect: It physically "staples" the TT cell to the tumor cell, triggering direct killing while bypassing the need for MHCMHC antigen presentation or natural TT cell receptor activation. This mechanism illustrates a novel approach to engaging the immune system in cancer therapy.

Immunomodulators: Cytokine Therapies

  • These represent early FDA-approved immunotherapies, though high toxicity limits their current use.

  • High-Dose Recombinant Interleukin-2 (IL-2): Approved in the 1990s1990s for metastatic renal cell carcinoma and metastatic melanoma. It promotes the differentiation of effector TT cells. Toxicities include lethal immuno-activation and the potential to promote TT regulatory (TregT_{reg}) cells, leading to paradoxical responses. Understanding these dynamics is crucial for optimizing treatment protocols.

  • Recombinant Interferon-Alpha: Approved for hairy cell leukemia. It works by inducing MHCMHC class II expression on tumor cells and promoting dendritic cell maturation. Side effects involve significant multi-organ toxicity, resembling severe symptoms experienced during viral infections, which emphasizes the need for careful patient management in administering these therapies.